Popular for newcomers to IV therapy
In the phase 2 trial, 72% of participants with prediabetes at baseline were able to achieve normal HbA1c levels after 48 weeks of retatrutide therapy, compared to just 22% in the placebo group
Peptide therapy can address a wide range of health concerns including fatigue, weight gain, poor sleep, low libido, slow recovery, inflammation, aging skin, cognitive decline, and compromised immunity
Healthcare providers recommend establishing a consistent weekly schedule that fits individual routines
CJC-1295 provides sustained growth hormone elevation while ipamorelin delivers precise, pulsatile releases that closely mimic your body natural GH patterns